Abstract

The myriad new molecular entities (NMEs) approved by the US Food and Drug Administration (FDA) in 2015 reflected both the opportunities and risks associated with the development of new medicines. On the one hand, the approval of 45 NMEs was among the highest ever recorded. Likewise, the diversity underlying the mechanistic basis of new medicines suggests continued broadening relative to the predominate trends of the past few decades. On the other hand, closer inspection indicates that business model decisions surrounding orphan indications and consolidation could be placing the industry in an ever-more precarious position, with severe implications for the sustainability of the entire enterprise.

Original languageEnglish
Pages (from-to)1046-1050
Number of pages5
JournalDrug Discovery Today
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Dive into the research topics of '2015 in review: FDA approval of new drugs'. Together they form a unique fingerprint.

Cite this